HomeCompareRFP vs MRK

RFP vs MRK: Dividend Comparison 2026

RFP yields 11.41% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $15.2K in total portfolio value· pulled ahead in Year 8
10 years
RFP
RFP
● Live price
11.41%
Share price
$21.92
Annual div
$2.50
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.5K
Annual income
$2,327.21
Full RFP calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — RFP vs MRK

📍 MRK pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRFPMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RFP + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RFP pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RFP
Annual income on $10K today (after 15% tax)
$969.43/yr
After 10yr DRIP, annual income (after tax)
$1,978.13/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $6,618.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RFP + MRK for your $10,000?

RFP: 50%MRK: 50%
100% MRK50/50100% RFP
Portfolio after 10yr
$50.1K
Annual income
$6,220.49/yr
Blended yield
12.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

RFP
Analyst Ratings
2
Buy
3
Hold
1
Sell
Consensus: Hold
Altman Z
2.2
Piotroski
9/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RFP buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRFPMRK
Forward yield11.41%2.81%
Annual dividend / share$2.50$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$42.5K$57.7K
Annual income after 10y$2,327.21$10,113.78
Total dividends collected$17.2K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: RFP vs MRK ($10,000, DRIP)

YearRFP PortfolioRFP Income/yrMRK PortfolioMRK Income/yrGap
1$11,841$1,140.51$11,213$373.04+$628.00RFP
2$13,931$1,262.08$12,667$512.06+$1.3KRFP
3$16,294$1,387.80$14,439$708.14+$1.9KRFP
4$18,952$1,517.01$16,640$988.16+$2.3KRFP
5$21,928$1,649.00$19,432$1,394.07+$2.5KRFP
6$25,246$1,783.09$23,057$1,992.90+$2.2KRFP
7$28,932$1,918.60$27,889$2,894.79+$1.0KRFP
8← crossover$33,012$2,054.87$34,518$4,286.29$1.5KMRK
9$37,514$2,191.27$43,912$6,494.35$6.4KMRK
10$42,467$2,327.21$57,714$10,113.78$15.2KMRK

RFP vs MRK: Complete Analysis 2026

RFPStock

Resolute Forest Products Inc., together with its subsidiaries, operates in the forest products industry in the United States, Canada, Mexico, and internationally. The company operates through four segments: Market Pulp, Tissue, Wood Products, and Paper. The Market Pulp segment offers virgin and recycled bleached Kraft pulp, which is used to make a range of consumer products, including tissue, packaging, specialty paper products, diapers, and other absorbent products. The Tissue segment provides various tissue products, such as recycled and virgin paper products for the away-from-home and retail markets; and sells parent rolls. The Wood Products segment produces construction-grade and spruce-pine-fir lumber products, wood chips, bed frame components, finger joints, and furring strips for pulp and paper mills, as well as I-joists for the construction industry. The Paper segment offers newsprint to newspaper publishers, as well as to commercial printers for uses comprising inserts and flyers. This segment also provides various uncoated mechanical papers, including supercalendered and white papers, as well as uncoated freesheet papers. Its specialty papers are used in books, retail inserts, direct mail, coupons, magazines, catalogs, bags, and other commercial printing applications. This segment sells specialty papers to commercial printers, direct mailers, publishers, catalogers, and retailers. The company also produces electricity at cogeneration facilities and hydroelectric dams. Resolute Forest Products Inc. is headquartered in Montreal, Canada.

Full RFP Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this RFP vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RFP vs SCHDRFP vs JEPIRFP vs ORFP vs KORFP vs MAINRFP vs JNJRFP vs ABBVRFP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.